T. Rowe Price Associates’s Amdocs DOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.61M Sell
55,355
-103,089
-65% -$7.54M ﹤0.01% 1566
2025
Q4
$12.8M Sell
158,444
-18,491
-10% -$1.49M ﹤0.01% 1178
2025
Q3
$14.5M Buy
176,935
+24,384
+16% +$2.11M ﹤0.01% 1138
2025
Q2
$13.9M Buy
152,551
+2,212
+1% +$198K ﹤0.01% 1051
2025
Q1
$13.8M Buy
150,339
+13,360
+10% +$1.17M ﹤0.01% 1042
2024
Q4
$11.7M Buy
136,979
+10,797
+9% +$947K ﹤0.01% 1126
2024
Q3
$11M Buy
126,182
+26,761
+27% +$2.25M ﹤0.01% 1123
2024
Q2
$7.85M Buy
99,421
+51,383
+107% +$4.22M ﹤0.01% 1145
2024
Q1
$4.34M Buy
48,038
+4,662
+11% +$425K ﹤0.01% 1256
2023
Q4
$3.81M Buy
43,376
+3,096
+8% +$258K ﹤0.01% 1292
2023
Q3
$3.4M Buy
40,280
+2,851
+8% +$258K ﹤0.01% 1283
2023
Q2
$3.7M Buy
37,429
+1,134
+3% +$107K ﹤0.01% 1269
2023
Q1
$3.49M Buy
36,295
+961
+3% +$88.9K ﹤0.01% 1270
2022
Q4
$3.21M Buy
35,334
+1,489
+4% +$127K ﹤0.01% 1290
2022
Q3
$2.69M Buy
33,845
+8,265
+32% +$700K ﹤0.01% 1343
2022
Q2
$2.13M Buy
25,580
+18,402
+256% +$1.52M ﹤0.01% 1595
2022
Q1
$590K Buy
7,178
+1,751
+32% +$137K ﹤0.01% 2265
2021
Q4
$406K Sell
5,427
-2,129
-28% -$160K ﹤0.01% 2487
2021
Q3
$572K Sell
7,556
-323
-4% -$25K ﹤0.01% 2312
2021
Q2
$610K Buy
7,879
+1,367
+21% +$106K ﹤0.01% 2295
2021
Q1
$457K Buy
6,512
+703
+12% +$53.1K ﹤0.01% 2413
2020
Q4
$412K Sell
5,809
-52
-0.9% -$3.26K ﹤0.01% 2319
2020
Q3
$336K Sell
5,861
-131
-2% -$7.83K ﹤0.01% 2248
2020
Q2
$365K Sell
5,992
-376
-6% -$23.2K ﹤0.01% 2181
2020
Q1
$350K Sell
6,368
-21
-0.3% -$1.41K ﹤0.01% 2140
2019
Q4
$461K Buy
+6,389
New +$435K ﹤0.01% 2175
2019
Q1
Sell
-3,515
Closed -$206K 2536
2018
Q4
$206K Buy
3,515
+198
+6% +$12.4K ﹤0.01% 2405
2018
Q3
$219K Buy
+3,317
New +$219K ﹤0.01% 2443
2013
Q4
Sell
-5,037,000
Closed -$185M 2493
2013
Q3
$185M Sell
5,037,000
-5,250,700
-51% -$198M 0.05% 424
2013
Q2
$382M Buy
+10,287,700
New +$367M 0.1% 249

Other funds holding DOX

T. Rowe Price Associates's DOX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Amdocs (DOX) stake by 65% in Q1 2026, selling an estimated $7.54M and leaving 55,355 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

T. Rowe Price Associates first reported a position in DOX in Q2 2013 and has held it in 30 quarters since. The position peaked at $382M in Q2 2013. 473 funds tracked by Wall St. Rank hold DOX as of Q1 2026.

  • T. Rowe Price Associates held 55,355 shares of Amdocs worth $3.61M as of Q1 2026.
  • T. Rowe Price Associates sold 103,089 Amdocs shares in Q1 2026, an estimated $7.54M.
  • Amdocs made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1566 holding.
  • T. Rowe Price Associates first reported a position in Amdocs in Q2 2013 and has held it in 30 quarters since.
  • T. Rowe Price Associates's Amdocs position peaked at $382M in Q2 2013.
  • 473 funds tracked by Wall St. Rank held Amdocs as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.